Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 2/20 | 0.44 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1159922 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL6322741 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL29122982 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL29400420 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL29454486 | 1.00 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| Hydrochloric Acid SCHEMBL8015976 | 0.98 | MEN1 (0.58) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| Hydrochloric Acid SCHEMBL8015981 | 0.98 | MEN1 (0.58) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| Hydrochloric Acid SCHEMBL8015977 | 0.98 | MEN1 (0.58) | MEN1KMT2ACYP1A2CYP3A4ACP3 | |
| SCHEMBL24044801 | 0.84 | MEN1 (0.48) | MEN1KMT2ACYP1A2CYP3A4GRM1 | |
| SCHEMBL381133 | 0.84 | CYP1A2 (0.55) | MEN1KMT2ACYP1A2CYP3A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853623-A | Preparation method of S- (+) -o-chlorophenylglycine methyl ester tartrate | 河南优凯制药有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-20040176637-A1 | Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation | ROBERT C. C. WU (TW) | 2004-09-09 | — | — | US | claimed |
| CN-120366352-B | Fusion enzyme L-2FL-D for directionally catalyzing D-o-chlorophenylglycine to be converted into L-o-chlorophenylglycine, and preparation method and application thereof | 合肥工业大学 | 2026-03-17 | — | — | CN | disclosed |
| CN-120366352-B | Fusion enzyme L-2FL-D for directionally catalyzing D-o-chlorophenylglycine to be converted into L-o-chlorophenylglycine, and preparation method and application thereof | 合肥工业大学 | 2026-03-17 | — | — | CN | disclosed |
| CN-120366352-A | Fusion enzyme L-2FL-D for directionally catalyzing D-o-chlorophenylglycine to be converted into L-o-chlorophenylglycine, and preparation method and application thereof | 合肥工业大学 | 2025-07-25 | — | — | CN | disclosed |
| CN-120366352-A | Fusion enzyme L-2FL-D for directionally catalyzing D-o-chlorophenylglycine to be converted into L-o-chlorophenylglycine, and preparation method and application thereof | 合肥工业大学 | 2025-07-25 | — | — | CN | disclosed |
| CN-119745876-A | Application of clopidogrel in preparation of medicines for preventing renal ischemia reperfusion injury | 中国人民解放军陆军军医大学第一附属医院 | 2025-04-04 | — | — | CN | disclosed |
| CN-119320814-A | Clopidogrel chiral intermediate and enzyme catalytic conversion method thereof | 黄淮学院 | 2025-01-17 | — | — | CN | disclosed |
| CN-117778360-A | Immobilized acylase and application thereof in synthesis of (S) -clopidogrel | 浙江工业大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-114507650-B | Leucine dehydrogenase mutant and application thereof in synthesis of (S) -o-chlorophenylglycine | 浙江工业大学 | 2023-09-05 | — | — | CN | disclosed |
| US-20230028700-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | FU RUI (CA) | 2023-01-26 | — | — | US | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| JP-2005218348-A | METHOD FOR PRODUCING OPTICALLY ACTIVE α-HYDROXY AMIDE | DAICEL CHEM IND LTD | 2005-08-18 | — | — | JP | disclosed |
| US-20040176637-A1 | Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation | ROBERT C. C. WU (TW) | 2004-09-09 | — | — | US | disclosed |
| US-20040176637-A1 | Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation | ROBERT C. C. WU (TW) | 2004-09-09 | — | — | US | disclosed |
| EP-0971915-B1 | METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2003-05-14 | — | — | EP | disclosed |
| US-6080875-A | REACTING A THIENYLGLYCIDIC DERIVATIVE WITH A PHENYLGLYCINE ESTER IN THE PRESENCE OF AN ALKALI METAL BOROHYDRIDE, DECYCLIZATION; PREPARING DRUGS FOR TREATING ANTI-PLATELET AGGREGATION AND ANTITHROMBOTIC ACTIVITIES | SANOFI-SYNTHELABO (FR) | 2000-06-27 | — | — | US | disclosed |
| EP-0971915-A1 | METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998039322-A1 | METHOD FOR PREPARING 2-THIENYLETHYLAMINE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176637-A1 | Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation | SRM, CES2, UGT1A6 | MEN1 4810/4885KMT2A 2170/4885CYP1A2 17/4885 |
| US-20230028700-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | GMPS, GUCY1A2, GUCY1B2 | MEN1 3149/4885KMT2A 3227/4885CYP1A2 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.